Nasdaq · Healthcare
Fulcrum Therapeutics, Inc. (FULC)
As-reported financials and recent SEC filings for Fulcrum Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$0
Net income
$-74.9M
Net margin
—
Diluted EPS
$-1.18
ROE
-21.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $-84.8M | $-21.9M | $-110.7M | $-112.6M | $-81.1M |
| Net income | $-74.9M | $-9.7M | $-97.3M | $-109.9M | $-80.8M |
| Diluted EPS | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →Largest Healthcare peers
Go deeper on FULC
Search Fulcrum Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.